Initial Treatment for Urinary Retention due to BPH

Management Algorithm for Acute Urinary Retention due to BPH

The initial treatment for patients with acute urinary retention due to BPH is catheterization followed by administration of an alpha blocker prior to attempting catheter removal 1
Immediate bladder decompression via urethral catheterization is recommended for patients with acute urinary retention due to BPH 2, 3
An alpha blocker, preferably a non-titratable one like tamsulosin or alfuzosin, should be started for patients with acute urinary retention due to BPH 3, 1
Alpha blocker therapy should be continued for at least 3 days before attempting a trial without catheter (TWOC) 1
After at least 3 days of alpha blocker therapy, attempt catheter removal 1
Alpha blockers, such as alfuzosin and tamsulosin, significantly improve TWOC success rates, with success rates of 60% and 47%, respectively, compared to placebo 1
Patients who have undergone successful TWOC should be informed about the increased risk of recurrent urinary retention 1
Alpha blocker therapy should be continued to reduce the risk of recurrent retention 1

If catheter removal fails after alpha blocker treatment, surgery is recommended 2, 3, 4
For patients who are not surgical candidates, options include intermittent catheterization, indwelling catheter, and prostatic stent placement 2, 3
Balloon dilation is not recommended as a treatment option for BPH 5
Prior history of alpha blocker side effects, unstable medical comorbidities, and certain medical conditions are contraindications to alpha blockers 3

All four alpha blockers (tamsulosin, alfuzosin, doxazosin, and terazosin) demonstrate similar clinical effectiveness in improving LUTS symptoms, with a 4-6 point improvement in AUA Symptom Index, which patients perceive as meaningful improvement 6, 7
Tamsulosin has less effect on blood pressure compared to other alpha blockers, making it a safer option for elderly patients and those with hypertension 6, 7
Alpha blockers improve maximum urinary flow rate (Qmax) and in acute urinary retention (AUR), they improve successful trial without catheter (TWOC) rates, with alfuzosin showing 60% vs 39% for placebo, and tamsulosin showing 47% vs 29% for placebo 8, 9

Doxazosin and terazosin require dose titration to minimize first-dose hypotensive effects, while tamsulosin and alfuzosin can be initiated without dose titration 7
Tamsulosin and extended-release alfuzosin are administered once daily, while immediate-release alfuzosin requires three times daily dosing, and doxazosin can be titrated up to 8mg daily, terazosin up to 10mg daily, and tamsulosin can be increased from 0.4mg to 0.8mg if needed 7

For patients with hypertension, doxazosin monotherapy was associated with higher incidence of congestive heart failure than other antihypertensive agents, suggesting separate management of hypertension may be needed 7
For acute urinary retention, alpha blockers should be prescribed prior to attempting a voiding trial, with at least three days of therapy before attempting trial without catheter 8, 9